Arterial and Venous Thrombotic Complications with Thalidomide in Multiple Myeloma

Archives of Medical Research

Volumn 39, Issue 2, 2008, Pages 257-258

  Alkindi, Salam ^a   Dennison, David ^b   Pathare, Anil ^b  

^a SULTAN QABOOS UNIVERSITY   (Oman)

^b SULTAN QABOOS UNIVERSITY HOSPITAL   (Oman)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTICOAGULANT AGENT; BETA 2 MICROGLOBULIN; BORTEZOMIB; DEXAMETHASONE; DEXTRAN; DOXORUBICIN; STEROID; THALIDOMIDE; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DEEP VEIN THROMBOSIS; ELECTROCARDIOGRAPHY; FEMALE; HEART INFARCTION; HUMAN; LETTER; LUNG EMBOLISM; MALE; MULTIPLE MYELOMA; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; STROKE; THROMBOEMBOLISM; THROMBOSIS; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PULMONARY EMBOLISM; THALIDOMIDE; TIME FACTORS; VENOUS THROMBOSIS;

EID: 37349098875     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2007.08.005     Document Type: Letter

References (7)

1. Disapenzieri A., and Kyle R.A. Multiple myeloma: clinical features and indications for therapy. Best Pract Res Clinic Haematol 18 (2005) 553-568
2. Zervas K., Dimopoulos A., Hatzicharissi A., Anagnostopoulos A., Papaioannou M., Mitsouli C.H., et al. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin, and dexamethasone (T-VAD doxil): a phase II multicentre study. Ann Oncol 15 (2004) 134-138
3. Potenza L., Luppi M., Morselli M., Saviola A., Ferrari A., Riva G., et al. Thrombotic complications associated with thalidomide in multiple myeloma: an old problem with new questions and quandaries in decision-making. Thromb Haemost 91 (2004) 834-836
4. Urbauer E., Kaufmann H., Nosslinger T., Radener M., and Drach J. Thromboembolic events during treatment with thalidomide. Blood 99 (2002) 4247-4248
5. Zangari M., Anaissie E., Barlogie B., Badros A., Desikan R., Gopal A.V., et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98 (2001) 1614-1615
6. Kaushal V., Kohli M., Zangari Fink L., and Mehta P. Endothelial dysfunction in antiangiogenesis associated thrombosis. J Clin Oncol 20 (2002) 3042-3044
7. Zangari M., Barlogie B., Anaissie E., Saghafifar F., Eddlemon P., Jacobson J., et al. Deep-vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 126 (2004) 715-721